Nabriva, an antibiotic biotech, recently announced that they were winding down its operations. While this is sad, it may not be so much a market failure problem in this particular case. Last week, a ...

Scientists are probing woolly mammoth and Neanderthal genetic codes for new compounds as today’s drugs lose potency.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

since the vast majority of products in the antibiotic pipeline – from early discovery through late-stage clinical development – come from biotech. According to the 2021 WHO analysis, 84% of ...

Today, antibiotics are the third largest-selling ... manufactured by Micrologix Biotech (Vancouver, BC). The two-part phase II trials are intended to assess the safety, pharmacokinetics, and ...

India has launched the first indigenous antibiotic for drug-resistant infections. Known as 'Nafithromycin,' the drug has been ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Finding #4: Unmet medical needs and associated premium pricing drive many biotech VCs’ investment decisions, with antibiotics as a major outlier. VCs expressed pride in helping bring to market ...

Tackling antibiotic resistance ... SO THERE’S NO STANDARD MODEL TO DEAL WITH IT” A biotechnology pioneered by Doudna offers a possible solution. Doudna is the Nobel Prize–winning co-inventor ...

known as BioCurious. There they would grow antibiotic resistant bacteria, and, along the way, learn how CRISPR technology works and how easy it might be for an individual to genetically engineer a ...

Repeated perinatal antibiotic exposure in very low-birth-weight preterm infants was associated with impaired lung function ...